In the race to find faster, more effective treatments for cancer, researchers have begun looking in unexpected places—like the pharmacy shelves where old drugs sit, long approved for other uses. This strategy, known as drug repurposing, is transforming how we approach cancer care. And in some cases, it’s doing more than saving time—it’s saving lives.
One of the most promising examples? A common diabetes medication is now being studied and used to treat certain rare forms of cancer. This surprising pivot illustrates the power of medical innovation and the urgent need for new solutions in oncology.
What is drug repurposing?
Drug repurposing involves taking an existing medication—already approved for one condition—and using it to treat another. This method has gained momentum in recent years because it significantly shortens the timeline for bringing therapies to patients. These drugs already have known safety profiles, dosing guidelines, and manufacturing protocols, which means fewer hurdles for regulatory approval.
Instead of starting from scratch, researchers build on what is already known, using new data and clinical trials to explore different therapeutic potentials. In cancer treatment, where time is critical, this approach has become a valuable tool.
The diabetes drug making waves in oncology
One of the best-known examples of repurposing is the use of metformin, a drug traditionally prescribed to manage type 2 diabetes. Metformin works by lowering blood sugar and improving insulin sensitivity, but researchers noticed something unusual: patients on metformin seemed to have lower rates of cancer incidence and mortality.
This observation led to a growing body of research. Now, metformin is being explored for its potential in treating rare cancers such as neuroendocrine tumors, ovarian cancer, and even glioblastoma. Its ability to alter metabolic pathways and inhibit certain cancer cell growth patterns has opened the door to targeted studies and early-phase clinical trials.
How the transition happens: from diabetes to cancer
The journey from diabetes drug to cancer therapy doesn’t happen overnight. It begins with observations in large population studies, often followed by laboratory research to understand the mechanisms involved. If results are promising, early-phase clinical trials are initiated to test safety and efficacy in the new context.
These trials may start with patients who have exhausted other treatment options, especially in the case of rare or treatment-resistant cancers. Metformin’s long-standing safety record makes it a compelling candidate for such off-label use, with a growing number of oncologists incorporating it as part of experimental or adjunctive therapies.
The medical benefits of repurposed drugs
For patients and providers, repurposed drugs offer several key advantages:
• Faster development timelines: Skipping early safety testing means patients can access treatments sooner. • Lower costs: These medications are often available as generics, making them affordable. • Better safety data: With years or even decades of use in other conditions, doctors have confidence in managing side effects.
In cancer care, where new drugs can take 10–15 years and billions of dollars to reach the market, repurposing offers a more agile solution. It’s not just smart science—it’s compassionate care.
Cautions and ethical considerations
As a doctor and oncologist, I always urge caution alongside enthusiasm. Not every promising lab result translates into real-world success. Repurposed drugs must still undergo rigorous trials to confirm their value in a new context. Using them prematurely or without clinical oversight can create false hope, delays in proven treatments, or unintended harm.
Ethically, it’s essential to communicate clearly with patients: repurposed medications are not miracle cures, but they can be powerful tools when used as part of a thoughtful, evidence-based treatment plan.
What this means for the future of cancer care
Metformin is not the only repurposed drug in the oncology spotlight. Others—like aspirin, statins, and anti-inflammatory medications—are also being studied for cancer prevention and treatment. This signals a broader shift toward precision medicine, where we look at the biology of disease, not just the label on the bottle.
By rethinking how we use familiar medications, we unlock new pathways for treatment—especially for patients facing rare, aggressive, or underfunded cancers. The repurposing strategy brings hope to families, accelerates innovation, and reminds us that progress doesn’t always require reinventing the wheel.
In a world where cancer treatments often come with high costs, long waits, and uncertain outcomes, drug repurposing is a rare bright spot. It leverages the science we already trust to find new answers for the diseases we fear most.
And in the case of a diabetes medication now helping to fight rare cancers, it proves that sometimes, the medicine we need is already within reach—we just need to see it differently.
